MedinCell’s partner Teva today announced refiling for approval of mdc-IRM and confirmed planned launch in the U.S. in H1 2023
November 3, 2022
Previous PostMedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
Next PostMedinCell signs a licence agreement with the Medicines Patent Pool to fight malaria transmission, as part of its global health mission
